The review found no eligible studies for this question.
An extended antiretroviral regimen administered to mothers for 28… showed no clear difference in infants with Severe Adverse Events compared with 1 week of antiretroviral prophylaxis (low certainty).
An extended antiretroviral regimen administered to mothers for 28… may leads to higher mothers with Severe Adverse Events compared with 1 week of antiretroviral prophylaxis (low certainty).
An extended NVP regimen administered to infants for 28 weeks showed no clear difference in infants with Severe Adverse Events compared with 1 week of antiretroviral prophylaxis (low certainty).
A once‐daily NVP regimen administered for 6 months showed no clear difference in infants with Severe Adverse Events compared with a once‐daily NVP regimen administered (high certainty).
An extended antiretroviral regimen administered to mothers for 28… showed no clear difference in infants with Severe Adverse Events compared with an extended NVP regimen administered to infants (low certainty).
An extended antiretroviral regimen administered to mothers for 28… may leads to higher mothers with Severe Adverse Events compared with an extended NVP regimen administered to infants (low certainty).
Summary of findings table ‐ Concizumab prophylaxis showed no clear difference in adverse events ‐ All adverse events compared with on‐demand therapy (low certainty).
It is very uncertain whether NPWT changes adverse events (fistulae formation) compared with the Bogota bag (very low certainty).
It is very uncertain whether suprasorb CNP system changes adverse events (fistulae formation) compared with the ABThera system (very low certainty).
Bamlanivimab showed no clear difference in adverse events: all grade by week 8 compared with placebo (low certainty).
Urtoxazumab (3.0 mg/kg) showed no clear difference in adverse events ‐ treatment emergent compared with placebo (low certainty).
Urtoxazumab (1.0 mg/kg) showed no clear difference in adverse events ‐ treatment emergent compared with placebo (low certainty).
The review found no eligible studies for this question.
Vitamin E leads to higher adverse events: haemorrhagic stroke compared with placebo (high certainty).
It is very uncertain whether intravenous changes adverse events: nausea and vomiting compared with oral cyclophosphamide (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.